A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The purpose of this study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa. Funding Source - FDA OOPD

Official Title

A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa

Eligibility Criteria

Ages Eligible for Study: Older than 2 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Male or female ≥2 years of age at the Screening visit. - Clinical diagnosis of RDEB with confirmation of COL7A1 genetic mutation. Key
Exclusion Criteria:
  1. - Medical instability limiting ability to travel to the investigative site. - Active infection with human immunodeficiency virus, hepatitis B or hepatitis C. - The presence of COL7 antibodies. - Evidence of systemic infection. - Evidence or history of squamous cell carcinoma at the site to be injected. - Evidence of or history of metastatic squamous cell carcinoma. - Known allergy to any of the constituents of the product. - Female who is pregnant or breastfeeding. - Receipt of a chemical or biological intervention for the specific treatment of RDEB in the past three (3) months prior to screening or anticipated/planned during the screening and treatment period for this study.


M. Peter Marinkovich, MD
M. Peter Marinkovich, MD
Dermatologist, Blistering disease specialist, Psoriasis specialist
Associate Professor of Dermatology

Contact us to find out if this trial is right for you.


Kunju J Sridhar, PhD